Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.6400
+0.0310 (5.09%)
At close: Aug 25, 2026, 4:00 PM EDT
0.6433
+0.0033 (0.52%)
After-hours: Aug 25, 2026, 7:58 PM EDT
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $8.70K in the quarter ending June 30, 2026, a decrease of -99.42%. This brings the company's revenue in the last twelve months to $-1.16M. In the fiscal year ending September 30, 2025, Outlook Therapeutics had annual revenue of $1.41M.
Revenue (ttm)
$-1.16M
Revenue Growth
n/a
P/S Ratio
-133.91
Revenue / Employee
n/a
Employees
17
Market Cap
155.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.41M | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | 8.15M | 5.06M | 163.84% |
| Sep 30, 2018 | 3.09M | -723.96K | -18.99% |
| Sep 30, 2017 | 3.81M | 831.94K | 27.92% |
| Sep 30, 2016 | 2.98M | -2.24M | -42.91% |
| Sep 30, 2015 | 5.22M | -3.83M | -42.33% |
| Sep 30, 2014 | 9.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| NRx Pharmaceuticals | 3.39M |
| Connect Biopharma Holdings | 2.95M |
| Milestone Pharmaceuticals | 2.34M |
| Kazia Therapeutics | 1.27M |
OTLK News
- 8 days ago - Outlook Therapeutics announces common stock, warrants offering - TheFly
- 8 days ago - Outlook Therapeutics $100M Spot Secondary re-offered at 99c - TheFly
- 8 days ago - Outlook Therapeutics 55.6M share Spot Secondary priced at 99c - TheFly
- 9 days ago - Outlook Therapeutics reports Q3 EPS (15c), consensus (8c) - TheFly
- 11 days ago - Outlook Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - Outlook Therapeutics Earnings release: Q3 2026 - Filings
- 11 days ago - Outlook Therapeutics Quarterly report: Q3 2026 - Filings
- 11 days ago - Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ - GlobeNewsWire